grapesharvester schreef op 26 augustus 2015 21:55:
Ik doel op het volgende stukje uit een lang verhaal Todd Campbell van Motley fool, te vinden op Yahoo finance vbij ABBVIE d.d. 22 augustus 2015:
AbbVie is also developing a next generation of autoimmune drugs to supplant Humira, including a JAK-1 inhibitor, ABT-494, that is in phase 2 trials as a treatment for rheumatoid arthritis. Additional immunology drugs that could insulate AbbVie's autoimmune disease market share down the road include ALX-0061, an anti-IL-6 nanobody, and ABT-122, a drug that combines an anti-TNF like Humira with an anti-IL-17 therapy. Results from ABT-122's mid-stage study are expected next year.
Even if AbbVie's R&D efforts in autoimmune disease come up short, AbbVie could still make up for any lost sales with other drugs in its product lineup.
Galapagos en filgotinib vallen hier miscchien onder including, maar worden niet genoemd. Toch jammer dat zij die troef van ABBVIE missen in hun verhaal.